
Xilio Therapeutics, Inc. (XLO) Stock Ticker
XLO right now
Market factors today
Unlock the full XLO picture
About Xilio Therapeutics, Inc.
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.
XLO stock facts
| Ticker symbol | XLO |
| Exchange | NASDAQ Global Select |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $59.4M |
| CEO | Rene Russo |
| Employees | 76 |
| Headquarters | Waltham, MA, US |
| IPO date | 2021-10-22 |
| Website | www.xiliotx.com |
What you can see for XLO on Tickr
Live XLO price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the XLO report.
Rankings
FAQ
What is the ticker symbol for Xilio Therapeutics, Inc.?
The ticker symbol for Xilio Therapeutics, Inc. is XLO, listed on the NASDAQ Global Select.
What is XLO?
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs,…